Filing Flows › Immunocore Holdings (IMCR) › How it makes money
How Immunocore Holdings (IMCR) makes money
Immunocore Holdings (IMCR) made $102M of revenue in the third quarter 2026 (Q3 2026), -1% from a year earlier.
Drawing the Sankey…
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $102M | 100.0% |
| Income tax | $153K | 0.1% |
| Operating cash flow | $20.1M | 19.7% |
| Free cash flow | $17.7M | 17.4% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $102M | -1% |
| Q2 2026 | $116M | +18% |
| Q1 2026 | $107M | +14% |
| Q4 2025 | $104M | +24% |
| Q3 2025 | $104M | +29% |
| Q2 2025 | $98.0M | +30% |
| Q1 2025 | $93.9M | +33% |
From Immunocore Holdings' 10-Q filed Nov 6, 2026 (on EDGAR).
Questions
How does Immunocore Holdings make money?
Immunocore Holdings (IMCR) made $102M of revenue in the third quarter 2026 (Q3 2026), -1% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.